Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 7, 2008 - Issue 2
Submit an article Journal homepage
122
Views
2
CrossRef citations to date
0
Altmetric
Review

Anticancer therapy in patients with porphyrias: evidence today

Antoine Thiery-Vuillemin Medical Oncology Unit, CHU Minjoz, Bvd Fleming, 25000 Besancon, France +33 03 81 66 87 05; [email protected]
, MD,
Loic Chaigneau Medical Oncology Unit, CHU Minjoz, Bvd Fleming, 25000 Besancon, France +33 03 81 66 87 05; [email protected]
, MD,
Nadine Meaux-Ruault Medical Oncology Unit, CHU Minjoz, Bvd Fleming, 25000 Besancon, France +33 03 81 66 87 05; [email protected]
, MD,
Cristian Villanueva Medical Oncology Unit, CHU Minjoz, Bvd Fleming, 25000 Besancon, France +33 03 81 66 87 05; [email protected]
, MD,
Thierry N'guyen Medical Oncology Unit, CHU Minjoz, Bvd Fleming, 25000 Besancon, France +33 03 81 66 87 05; [email protected]
, MD,
Tristan Maurina Medical Oncology Unit, CHU Minjoz, Bvd Fleming, 25000 Besancon, France +33 03 81 66 87 05; [email protected]
, MD,
Ulrich Stein Medical Oncology Unit, CHU Minjoz, Bvd Fleming, 25000 Besancon, France +33 03 81 66 87 05; [email protected]
, MD,
Véronique Lorgis Medical Oncology Unit, CHU Minjoz, Bvd Fleming, 25000 Besancon, France +33 03 81 66 87 05; [email protected]
, MD,
Martin Demarchi Medical Oncology Unit, CHU Minjoz, Bvd Fleming, 25000 Besancon, France +33 03 81 66 87 05; [email protected]
, MD &
Xavier Pivot Medical Oncology Unit, CHU Minjoz, Bvd Fleming, 25000 Besancon, France +33 03 81 66 87 05; [email protected]
, MD PhD show all
Pages 159-165 | Published online: 06 Mar 2008

Bibliography

  • Anderson KE, Sassa S, Bishop DF, et al. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: The Metabolic and Molecular Bases of Inherited Disease. 8th edition. Scriver CR, Beaudet A, Sly WS, Valle D, editors. New York: McGraw-Hill; 2001. p. 2991-3062
  • Moore MR, McColl KE, Rimington C, et al. Disorders of Porphyrin Metabolism. New York: Plenum Publishing Corporation; 1987
  • Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine 1992;71:1-13
  • Crimlisk HL. The little imitator-porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry 1997;62:319-28
  • Murphy GM. The cutaneous porphyrias: a review. Br J Dermatol 1999;140:573-81
  • Hindmarsh JT, Oliveras L, Greenway DC. Biochemical differentiation of the porphyrias. Clin Biochem 1999;32:609-19
  • de Rooij WM, Edixhoven A, Wilson JH. Porphyria: a diagnostic approach. In: The Porphyrin Handbook. Kadish KM, Smith KM, Guilard R, editors. St Louis: Elsevier; 2003. p. 211-45
  • Website of European Porphyria Initiative (EPI). Available at: www.porphyria-europe.com [Last accessed February 2008]
  • The Norweigan Porphyria Centre (NAPOS) is responsible for the development of this multi-language drug database. Available at: www.drugs-porphyria.org [Last accessed February 2008]
  • University of Cape Town website – Porphyria South Africa. Available at: www.uct.ac.za/depts/porphyria [Last accessed February 2008]
  • Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine 1992;71:1-13
  • Kauppinen R, Mustajoki P. Acute hepatic porphyria and hepatocellular carcinoma. Br J Cancer 1988;57:117-20
  • Andersson C, Lithner F. Hypertension and renal disease in patients with acute intermittent porphyria. J Intern Med 1994;236:169-75
  • Andersson C, Bjersing L, Lithner F. The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria. J Intern Med 1996;240:195-201
  • Andant C, Puy H, Deybach JC, et al. Occurrence of hepatocellular carcinoma in a case of hereditary coproporphyria. Am J Gastroenterol 1997;92:1389-90
  • Laiwah AA, Mactier R, McColl KE, et al. Early-onset chronic renal failure as a complication of acute intermittent porphyria. Q J Med 1983;52:92-8
  • Linet MS, Gridley G, Nyren O, et al. Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden. Am J Epidemiol 1999;149:1010-5
  • Kaczynski J, Hansson G, Thunell S, et al. Erythrocyte porphobilinogen deaminase activity and primary liver cancer. J Intern Med 1995;237:309-13
  • Kauppinen R. Porphyrias. Lancet 2005;365:241-52
  • Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine 1992;71:1-13
  • Jeans JB, Savik K, Gross CR, et al. Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series. Am J Med Genet 1996;65:269-73
  • Zadra M, Grandi R, Erli LC, et al. A. Treatment of seizures in acute intermittent porphyria: safety and efficacy of gabapentin. Seizure 1998;7:415-6
  • Holroyd S, Seward RL. Psychotropic drugs in acute intermittent porphyria. Clin Pharmacol Ther 1999;66:323-5
  • Forget F, Awada A, Klastersky J. Anticancer chemotherapy in a patient with prior history of acute intermittent porphyria: a case report and review of the literature. Support Care Cancer 2001;9:465-6
  • Aggarwal N, Bagga R, Sawhney H, et al. Pregnancy with acute intermittent porphyria: a case report and review of literature. J Obstet Gynaecol Res 2002;28:160-2
  • Martin M, Pienkowski T, Mackey J, et al.; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-13
  • Bonomi P, Blessing J, Ball H, et al. A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989;37:354
  • Kaern J, Trope C, Kjorstad KE, et al. A phase II study of 5-fluorouracil/cisplatin in recurrent cervical cancer. Tidsskr Nor Laegeforen 1990;110:2759
  • Weiss G, Green S, Hannigan E, et al. A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. Gynecol Oncol 1990;37:354
  • Moore DH, McQuellon RP, Blessing JA, et al. A randomized phase III study of cisplatin versus cisplatin plus paclitaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Proc Am Clin Oncol 2001;20:201a
  • Posner MR, Hershocl D, Le-Lann L, et al.; for the TAX 324 Study Group. Scientific Special Session: Docetaxel added to induction therapy in head and neck cancer. Paper presented at 42nd Annual Meeting of the American Society for Clinical Oncology (ASCO). Atlanta, GA. 2006 June 2-6
  • Taxotere® Prescribing Information, revised December 2006. Bridgewater, NJ: Sanofi-Aventis US
  • Corets JE, Pazdur R. Docetaxel. J Clin Oncol 1995;13:2643-55
  • Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36:99-114
  • Bruno R, Hille D, Riva A, et al. Population pharmacokinetic/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998;16:187-96
  • Bruno R, Vivier N, Veyrat-Follet C, et al. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs 2001;19:163-9
  • McLeod HL, Kearns CM, Kuhn JG, Bruno R. Evaluation of the linearity of docetaxel pharmacokinetics. Cancer Chemother Pharmacol 1998;42:155-9
  • Marland M, Gaillard C, Sanderink G, et al. Kinetics, distribution, metabolism and excretion of radiolabeled Taxotere (14C-RPR 56976) in mice and dogs. Proc Am Assoc Cancer Res 1993;34:393 (Abstract)
  • Nallani SC, Genter MB, Desai PB. Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel. Cancer Chemother Pharmacol 2001;48:115-22
  • Nallani SC, Goodwin B, Buckley AR, et al. Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes. Cancer Chemother Pharmacol 2004;54:219-29
  • Thunell S, Pomp E, Brun A. Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias. Br J Clin Pharmacol 2007;64:668-79
  • Kappas A, Sassa S, Galbraith RA, Nardaman Y. The porphyrias. In: The Metabolic Basis of Inherited Diseases. 6th edition. Scriver CR, Beaudet AL, Sly WS, Valle D, editors. New York: McGraw-Hill; 1989. p. 1305-66
  • de Matteis F. Disturbances of liver porphyrin metabolism caused by drugs. Pharmacol Rev 1967;19:523-57
  • Cochon AC, Aldonatti C, San Martin de Viale LC, de Calmanovici RW. Evaluation of the porphyrinogenic risk of antineoplastics. J Appl Toxicol 1997;17:171-7
  • Palma-Carlos AG, Palma-Carlos ML, Lourenco MG, et al. Effect of alkylating agents on haem metabolism. S Afr J Lab Clin Med 1971;25:81-4
  • Rizzardini M, Ferraroli A, Dal Fiume D, et al. Cyclophosphamide impaired regulation of hepatic heme metabolism. Experientia 1984;40:1390-2
  • Samuels B, Bezwoda WR, Derman DP, et al. Chemotherapy in porphyria. S Afr Med J 1984;65:924-6
  • Scarlett JD, Corry J, Jeal PN. Cytotoxic chemotherapy and radiotherapy in a patient with breast cancer and variegate porphyria (VP). Aust NZ J Med 1995;25:742-3
  • Wehmeier A, Fitcher J, Goerz G, et al. Polychemotherapy of acute myelogenous leukemia in a patient with acute intermittent porphyria. Klin Wochenschr 1987; 65:338-40
  • Smith I, Procter M, Gelber RD, et al.; for the HERA Study Team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36
  • O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004
  • Demetri GD, Von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80
  • Richardson PG, Barlogie B, Berenson J, et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 2006;106:1316-9
  • Au WY, Lee J. Imatinib mesylate (STI-571) and porphyria cutanea tarda in a Chinese patient. Haematologica 2005;90:ECR18
  • Breccia M, Latagliata R, Carmosino I, et al. Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia. Leukemia 2004;18:182
  • Ho AY, Daecon A, Osborne G, et al. Precipitation of porphyria cutanea tarda by imatinib mesylate? Br J Haematol 2003;21:375
  • Cabanillas M, Peteiro C, Toribio J. Multiple myeloma associated with porphyria cutanea tarda: a possible role of bortezomib? Dermatology 2006;213:246-7

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.